Biotech Values

[jq1234]

To me ABT and GSK are long shot, not because they are not interested, but because AMR101 will overlap with one of their existing drugs. To buy AMRN today will be quite expensive for a drug that needs outcome trial substantially underway before filing NDA. It doesn't seem it is as attractive to these two as to say others like PFE, MRK, AZN from my point of view, thus I highly doubt they can outbid other big pharmas in similar space.